GETTYSBURG, Pa. (December 4th, 2022) — OPEN MINDS invites you to learn how personalized digital therapeutics are being used to treat cognitive impairments during the upcoming webinar: Next Generation Add-On Treatment Of Inattention In ADHD: A Discussion Regarding A New Prescription Digital Therapeutic that is scheduled for December 14th, at 1:00 pm ET.
OPEN MINDS announced today that they will host a webinar in partnership with a leading digital medicine company pioneering the development of cognitive treatments through game-changing technologies, Akili Interactive Labs, Inc., to discuss prescription digital therapeutics (PDTx) to potentially address the ongoing cognitive health crisis continues to be a clinical and economic burden in the United States.
Millions of people do not receive adequate treatment for cognitive impairment. For example, research has shown that the inattention and focusing difficulty seen in people with ADHD contribute to its classification as a cognitive impairment, but a general lack of awareness of these issues leads some to see ADHD as purely behavioral. This misappropriation has a negative effect on over 16 million people who have been diagnosed with ADHD in the United States, including over 6 million children. Although traditional ADHD management combines medications and psychosocial services, in many cases these treatments alone do not sufficiently manage ADHD symptoms. There is a need for a novel approach to treating ADHD that can complement a multimodal treatment plan.
“Akili continues to challenge traditional perceptions of medicine through the creation of the first and only prescription video game treatment for children (8-12) with primarily inattentive and combined-type ADHD, authorized by the U.S. Food and Drug Administration (FDA),” said Paul Duck, Senior Associate at OPEN MINDS. “Akili spent years collaborating with neuroscientists and acclaimed entertainment and technology designers studying the therapeutic potential of computerized interactions that could act as therapeutic to teach and focus on the brain functions that need work to combat inattention. I’m truly excited by the promise of PDTx as a modality to improve the patient experience and improve treatment adherence and health outcomes.”
Everyone deserves to have access to new and innovative treatments that address gaps in the current treatment landscape. But where do PDTx fit within the ADHD treatment protocol? How do they elevate the standard of care in ADHD? This session will highlight the role of PDTx in the management of ADHD with a focus on gaps in the current standard of care and strategies to navigate the access landscape for PDTx.
Learning Objectives: Upon completion of this discussion, participants should be able to:
- Understand the cognitive health crisis that exists today and the promise of PDTx to provide a solution
- Discuss ADHD and the gaps within the current standard of care
- Discuss the place in therapy and treatment protocol of current PDTx to treat inattention in ADHD
- Understand strategies to help overcome the challenges of PDTx coverage, including formulary decision making, coding, billing, and reimbursement
Don’t miss the Next Generation Add-On Treatment Of Inattention In ADHD: A Discussion Regarding A New Prescription Digital Therapeutic on December 14th, at 1:00 pm ET. This webinar is available free of charge; however, attendees must register in advance.
About Akili Interactive Labs, Inc.
Akili is pioneering the development of cognitive treatments through game-changing technologies. Our approach of leveraging technologies designed to directly target the brain establishes a new category of medicine – medicine that is validated through clinical trials like a drug or medical device, but experienced like entertainment. Akili’s platform is powered by proprietary therapeutic engines designed to target cognitive impairment at its source in the brain, informed by decades of research and validated through rigorous clinical programs. Driven by Akili’s belief that effective medicine can also be fun and engaging, Akili’s products are delivered through captivating action video game experiences. For more information, please visit www.akiliinteractive.com.
About OPEN MINDS
OPEN MINDS is a national market intelligence, management consulting, and marketing services firm specializing exclusively in the markets of the health and human service field that serve consumers with chronic conditions and complex support needs. OPEN MINDS’ mission is to provide payers, service provider organizations, and technology and scientific firms that serve these consumers with the market and management knowledge needed to improve their organizational efficiency and effectiveness. Learn more at www.openminds.com.